Pretherapeutic expression of the hOCT1 gene predicts a complete molecular response to imatinib mesylate in chronic-phase chronic myeloid leukemia.
about
Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacologySLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.Identifying and validating a combined mRNA and microRNA signature in response to imatinib treatment in a chronic myeloid leukemia cell line.Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatmentMolecular response to imatinib & its correlation with mRNA expression levels of imatinib influx & efflux transporters in patients with chronic myeloid leukaemia in chronic phase.OCT1 and imatinib transport in CML: is it clinically relevant?Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia.Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.Pharmacogenetics and Pharmacogenomics of Targeted Therapeutics in Chronic Myeloid Leukemia.Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance.Molecular Response to Imatinib and Its Correlation with mRNA Expression Levels of Imatinib Influx Transporter (OCT1) in Indian Chronic Myeloid Leukemia PatientsA common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia.
P2860
Q27026858-4CD4889A-763C-4693-BAB2-54F30DAEE6E0Q34525644-B1D61ADE-437A-49D2-A8EB-2489F21A8597Q34703835-4983C3F1-4935-4EF5-BC9B-E25C86B26BB5Q35922779-5C63F407-856B-44C0-AE6F-87CF9D29D5DDQ36184500-477BCD7C-84D6-47B0-9896-74643E7E1592Q38540022-499ABB4B-A30C-4A21-8C99-4EA24FED934EQ38843265-C4552D55-6485-460F-A978-5872785E90BBQ38902116-CA2B7B0D-2262-4000-9F29-4C1828B59005Q39175179-96394E72-FD8C-421D-8932-D0F42F992104Q39429836-D2E2419F-A2DF-4CD6-A494-B69D88D4CAD7Q41501849-BB64C075-BE62-4340-A64D-7F3F122E48D2Q47117554-215B21B6-B3D9-4C13-B0A9-BE2B83C6684DQ54240000-CF68277E-DF20-41EA-8D5A-0F85E45E6CFA
P2860
Pretherapeutic expression of the hOCT1 gene predicts a complete molecular response to imatinib mesylate in chronic-phase chronic myeloid leukemia.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Pretherapeutic expression of t ...... hase chronic myeloid leukemia.
@en
Pretherapeutic expression of t ...... hase chronic myeloid leukemia.
@nl
type
label
Pretherapeutic expression of t ...... hase chronic myeloid leukemia.
@en
Pretherapeutic expression of t ...... hase chronic myeloid leukemia.
@nl
prefLabel
Pretherapeutic expression of t ...... hase chronic myeloid leukemia.
@en
Pretherapeutic expression of t ...... hase chronic myeloid leukemia.
@nl
P2093
P2860
P356
P1433
P1476
Pretherapeutic expression of t ...... phase chronic myeloid leukemia
@en
P2093
Alline Didone
Antonio Lancha Ruiz
Dalton de Alencar Fischer Chamone
Ismael Severino Lima
Luciana Nardinelli
Mafalda Megumi Yoshinaga Novaes
Mariana Marchiani
Mariana Serpa
Patricia de Barros Ferreira
P2860
P304
P356
10.1159/000336610
P577
2012-04-13T00:00:00Z